<DOC>
	<DOC>NCT01229410</DOC>
	<brief_summary>This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.</brief_summary>
	<brief_title>Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy</brief_title>
	<detailed_description />
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction) Visual acuity in the nonstudy eye better than 20/200 History of pars plana vitrectomy or retinal detachment surgery in the study eye Surgery or laser treatment in the study eye within 3 months Use of brimonidine, apraclonidine or other topical alpha2agonist in either eye within 2 weeks Intraocular infection or inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>